Skip to main content
Ondine Biomedical Inc. logo

Ondine Biomedical Inc. — Investor Relations & Filings

Ticker · OBI ISIN · CA68234M2058 LEI · 9845005B69E07CGF4A56 TSXV Manufacturing
Open in API
Filings indexed 223 across all filing types
Latest filing 2025-09-23 Environmental & Social …
Country CA Canada
Listing TSXV OBI

About Ondine Biomedical Inc.

https://ondinebio.com/

Ondine Biomedical Inc. is a life sciences company that develops and commercializes photodisinfection-based therapies to prevent and treat a broad spectrum of infections, including those caused by drug-resistant pathogens. The company's patented platform technology involves applying a photosensitive agent to a targeted area, followed by illumination with non-thermal laser light. This process creates an oxidative burst that rapidly destroys pathogens like bacteria, viruses, and fungi without inducing microbial resistance. Its lead product, Steriwave™, is a nasal decolonization therapy used to eradicate pathogens in the nasal cavity, primarily to reduce the risk of healthcare-associated infections (HAIs) such as post-operative surgical site infections. The company's product pipeline is exploring applications for chronic rhinosinusitis, burns, wounds, and ventilator-associated pneumonia.

Recent filings

Filing Released Lang Actions
Steriwave Now Protecting Patients with Cancer
Environmental & Social Information Classification · 100% confidence The document is a press release distributed via the RNS (Reach) service, announcing that The Mater Hospital has adopted the company's 'Steriwave' product. It provides details on the clinical benefits and the partnership, but it does not constitute a formal financial report, audit, or regulatory filing. As it is a general corporate announcement regarding business operations and product adoption, it falls under the 'Regulatory Filings' (RNS) category as the fallback for miscellaneous corporate news.
2025-09-23 English
Notice of Interim Results & Investor Presentation
Report Publication Announcement Classification · 100% confidence The document is a short announcement (under 5,000 characters) from Ondine Biomedical Inc. stating that it will publish its interim financial results on a future date (26 September 2025) and providing details for an upcoming investor presentation. Per the 'Menu vs Meal' rule, this is an announcement of a report, not the report itself, and therefore qualifies as a Report Publication Announcement (RPA).
2025-09-19 English
Ondine Presents Major Economic Benefits at ICPIC
Regulatory Filings Classification · 100% confidence The document is a press release distributed via the London Stock Exchange's 'Reach' service (RNS). It announces that Ondine Biomedical Inc. presented clinical and economic data at the ICPIC 2025 conference. While it contains information about the company's technology and research, it is a corporate announcement of news/events rather than a formal financial report, proxy statement, or regulatory filing. As it does not fit into specific categories like 10-K, ER, or IP, it falls under the general regulatory/corporate announcement category.
2025-09-18 English
Steriwave proven to be effective against C Auris
Regulatory Filings Classification · 100% confidence The document is a press release distributed via the RNS (Regulatory News Service) 'Reach' platform. It discusses the effectiveness of the company's 'Steriwave' technology against a specific fungus (C. Auris) and mentions upcoming presentations. It does not constitute a formal financial report, audit, or governance filing, but rather a general corporate announcement regarding product efficacy and public health, which falls under the 'Regulatory Filings' (RNS) category as a catch-all for miscellaneous corporate news.
2025-09-15 English
Grant of Options
Regulatory Filings Classification · 98% confidence The document is an RNS announcement from Ondine Biomedical Inc. regarding the 'Grant of Options' to a key consultant. This involves the issuance of new share options, which falls under capital changes or share-related announcements. Since it specifically details the grant of options to an individual (consultant) rather than a general share issue or a director's personal dealing, it is best classified as a share-related capital change announcement.
2025-09-12 English
Steriwave Featured on CNBC’s Worldwide Exchange
Regulatory Filings Classification · 100% confidence The document is a press release distributed via the RNS (Regulatory News Service) 'Reach' platform. It discusses media coverage of the company's technology on CNBC and clarifies a misstatement regarding a board member. It does not contain financial results, governance reports, or other specific filings, and is categorized as a general regulatory announcement/press release.
2025-09-10 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.